- Home
- CDMO Services
- Biologics CDMO
- ADC CDMO
- Oligonucleotide CDMO
- Antibody & AOC CDMO
- Antibody & AOC Candidate Assessment & CMC Strategy
- Cell Line Construction, Screening, and Library Building
- Antibody & AOC Cell Culture Process Development
- Antibody & AOC Downstream Process Development
- Antibody & AOC Preparation Process Development
- Antibody & AOC Analytical Method Development
- Antibody & AOC Commercial Manufacturing
- Integrated CMC Development
- Cell Culture Media Services
- Support
- Case Studies
- Glycosylation Profile Optimization
- Fragment Reduction
- Aggregate Removal
- Low-Molecular-Weight Impurity Removal
- Downstream Process Characterization
- Antibody Process Characterization
- Protein Oxidation Mitigation Through Formulation Optimization
- Reducing Protein Aggregation in a Bispecific Antibody Formulation
- Rapid Development of a Stable Cell Line for Bispecific Antibody Production
- Accelerated Cell Culture Process Development for a Bispecific Antibody Program
- Late-Stage Cell Culture Process Optimization for Improved Antibody Productivity
- Accelerated Purification Process Development for a Complex Antibody Program
- Downstream Process Optimization for Improved Product Recovery
- Accelerating Formulation Development for a Bispecific Antibody Program
- High-Concentration Formulation Optimization for a Bispecific Antibody Injection
- CEX Method Optimization for Improved Charge Variant Analysis
- LC-MS-Based Identification of Polysorbate Degradation Pathways
- Manufacturing Capabilities
- Case Studies
- About Us
- Contact Us





